Event Date/Time: Oct 21, 2008
End Date/Time: Oct 23, 2008
Oct 21, 2008
Early Registration Date:
Jun 20, 2008
Abstract Submission Date:
Jun 06, 2008
Paper Submission Date:
Jun 06, 2008
EPFIA has called for a ban on re-packaging, stricter rules on auditing and controls in the supply chain, and the application of penalties for trafficking in counterfeits.
European Commission is in consultation to decide what legislation mandates to order to reduce counterfeit drugs, including: batch pedigrees, obligatory product seals, mass serialisation, mandatory audits and tight requirements for distribution stakeholders.
MHRA; General Manager, Michael Deats, will explain how the group is implementing strategic and operational measures designed to minimise the risk of counterfeit medicines and medical devices reaching patients through both the regulates and unregulated supply chains.
PSC is the annual event that has been working with industry and international regulatory bodies for years to disseminate important information to the industry and to bring the right people together to discuss realistic measures to deter counterfeiting of medicines and secure the supply chain.
Mark you calendar for this yearâ€™s must attend security event for pharmaceutical manufactures
â€œThe annual Pharma Secure Chain conference is the industry dedicated event to discussing the important counterfeit issues in pharmaâ€ - Tom Bos, Organon
Previous International Leader Speaker Panel included:
Harvey Bale, Director General, International Federation of Pharmaceutical Manufacturers Association (IFPMA)
Valerio Reggi, Health Technology and Pharmaceuticals, World Health Organisation
Graham Smith, Supply Chain Project Director, AstraZeneca & Chairperson, EFPIA Coding Group
Walter Bergamaschi, Director General for Information Systems and Statistics, Italian Ministry of Health
Laurent MochÃ©, Director of Inspection, at the French Regulatory Agency AFSSaPS
Josee Hansen, Chief Inspector, at the Dutch Health Care Inspectorate
Els Pasmooij from Amgen Europeâ€™s Security Programme: How they are strengthening their anti-counterfeiting toolbox
Brad Elrod from Pfizer
Christina SchÃ¼tze, Merck Seronoâ€™s
Andrew Jackson from Novartis
Yves Juillet, President of Leem and Advisor to IFPMA and WHO IMPACT
Ingrid Kempf, Senior Commercial Manager, Bristol Myers Squibb
Lew Kontnik, Director Brand Protection and Business Continuity, Amgen
Mark Davison, VP Pharmaceuticals, SICPA Product Security S.A.
Andrew Jackson, Deputy Head, Global Corporate Security, Novartis
Henk J. de Jong, Director International Scientific Relations, Servier Research Group, France
Juval Aviv, President & CEO, Interfor Inc.
Nimo Ahmed, Enforcement & Intelligence, Medicines and Healthcare products Regulatory Agency (MHRA)
Benoit Godart, Seconded Expert, Financial & Property Crime Unit, EUROPOL
Dieter Wurche, Technical AttachÃ©, WORLD CUSTOMS ORGANISATION
Monika Derecque-Pois, Secretary General, EUROPEAN ASSOCIATION OF WHOLESALERS (GIRP)
Aaron Graham, Vice President and Chief Security Officer, Purdue Pharma
David Weatherby, EPC Global European Adoption Programme Manager, GS1 UK
Heinz Kobelt, Secretary General, European Association of Euro-Pharmaceutical Companies, (EAEPC)
Geoff Power, Director, Packaging Security, Global Quality Assurance, GlaxoSmithKline
Matthias Pfletschinger, Project Manager Track & Trace, Global Supply Chain Management, Novartis Pharma AG
David Teale, Product Security Director, ASTRAZENECA
Rob Whewell, Vice President Sales, AEGATE
Alain Roudergues, Secretary General, CERP Rouen - SECOF